were calculated for each treatment strategy and severity level. Four types of items were surveyed: treatment strategy for VCF (hospitalization only, hospitalization to outpatient, outpatient visit only, D:follow-up only, F:other), treatment period of each VCF therapy (length of stay and outpatient visit), examination item (physical examination, laboratory test) and therapeutic regimens (use of cast on or hardiffort corest, rehabilitation, nerve block, medication). Severity of VCF was classified into three levels: status 1 (lumbar back pain/ADL impairment; neurological symptoms), status 2 (simplified, simplified status 3 (simplified + signs). RESULTS: The questionnaire was administered to 83 patients, and 82% of responders (response rate 82%) were received. Of these, 65 responses were available for estimation. When considering the proportions of treatment strategies (A to C), the expected medical costs for each status were: status 1: US $16,37, status 2: US $4485 and status 3: US $7962 (US $ = 92 JPY). The expected costs from the perspective of CMM for a patient with osteoporotic VCF in Japan was estimated at US $4,032, and the total annual costs of CMM for VCF on a national scale were estimated to be US $1.8 billion. CONCLUSIONS: Japan being an aging society, the burden of illness for VCF is a significant issue. Further standardization and customization of treatment modalities are expected for optimal allocation of medical resources.

AN EXPLORATORY EVALUATION OF THE COST-EFFECTIVENESS OF RITUXIMAB AND ABATCEPT IN THE TREATMENT OF MILD TO SEVERE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO A TUMOUR NECROSIS FACTOR INHIBITOR IN CANADA

Jung E, Mystry B
Hôpital de la Loire, Mississauga, ON, Canada

OBJECTIVES: Rituximab (RTX) and abatacept (ABAT) are novel therapies to treat moderate to severe Rheumatoid Arthritis (RA). This analysis was conducted to evaluate the cost-effectiveness of these two therapies in patients with active RA who have had an inadequate response to anti-tumour necrosis factor (TNF) inhibitor treatment from the Ontario Ministry of Health perspective. METHODS: A cost-utility model was used to evaluate the direct costs and outcomes of a standard Canadian treatment sequence in the absence and presence of either RTX + methotrexate (MTX) or ABAT + MTX after failure of one anti-TNF. The model simulated 10,000 RA patients over a life time. RTX and ABAT were evaluated against the following standard Canadian treatment sequence after failure of one anti-TNF (etanercept): adalimumab + MTX, infliximab + MTX, leflunomide, gold, cyclosporine and palliative care. Baseline characteristics from REFLEx (Randomized Evaluation of Long-term Efficacy of Rituximab in RA) clinical trial were: mean age, 52.2 years; mean HAQ score, 1.88. ACR score, response rates from RCTs were placebo-adjusted to minimize bias from cross-trial comparisons. All relevant direct costs were included in the model including drug costs, administration and monitoring, and adverse events. Observational data were used to estimate long-term HAQ progression and average time on treatment for patients responding to therapy. Costs and benefits were discounted at 5% per annum. RESULTS: The introduction of RTX following failure of one biologic resulted in a gain of 0.443 QALYs at an additional total cost of $3710 resulting in an ICER of $8380/QALY. The introduction of ABAT following failure of one biologic resulted in a gain of 0.387 QALYs at an additional total cost of $18,588 resulting in an ICER of $48,800/QALY. CONCLUSIONS: Rituximab is economically attractive from a Canadian payer perspective and is a cost effective treatment option over abatacept when compared in the studied population.

MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes Studies

IMPACT OF A SUPPORT PROGRAM ON THE TREATMENT COMPLIANCE IN OSTEOPOROSIS PATIENTS

Guzzo MR, Muramatsu AH
Praditno Rocha Quimions & Farmaceuticos SA; São Paulo, São Paulo, Brazil, "Universidade Federal de São Paulo Sao Paulo, São Brazil

OBJECTIVES: To assess the extension in which the participation of a patient in a support program contributes with increased osteoporosis treatment compliance. Trials demonstrated that the compliance rates to oral bisphosphonates therapy present a significant drop along the first year of treatment and continue declining year after year. The objective of a support program is to provide patient's support providing information about the disease, to interchange experiences with other patients, provide high calcium content nutrition tips and proper physical activities. METHODS: Quantitative study conducted through personal and individual interviews using a structured questionnaire. Two hundred and twenty interviews were conducted with female patients that concluded the bisphosphonate treatment, divided in two groups: one hundred-two registered and one hundred and eighteen non-registered into a support program. RESULTS: The average treatment period with bisphosphonate between the patients registered in the program is of 11 months vs. 4 months for non-registered patients. The main cause of impact on the continuous use of bisphosphonates of the patients non-registered in a support program include the treatment side effects (28% vs. 17%, p < 0.01), and non-adherence (15% vs. 24%, p < 0.01). From the total of patients interrupting the intake of bisphosphonate due to side effects the largest number are due to gastric problems. However, the patients registered in a support program reach the treatment final (34% vs. 15%; p < 0.01). CONCLUSIONS: The patients registered in a support program present the tendency to follow the prescription and remain for a longer time period in the therapy.

It is perceived that when the patients has access to wider information about the disease, which is one of the main objectives of a treatment support program, the therapy discontinuation rate due to side effects is lower. Because the patients are aware about the occurrence of gastric issues, they properly follow the guidelines, avoiding them and reaching the treatment final.

QUALITY OF LIFE AND COMPLIANCE IN GIRLS WITH ADOLESCENT IDIOPATHIC SCOLIOSIS

Rivett L, Conger A
The University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa

OBJECTIVES: The Brace Questionnaire (BrQ) is a recently-developed, condition-specific tool used to measure quality of life (QoL) in subjects born with spinal bracing. While corrective bracing for adolescent idiopathic scoliosis (AIS) has more favourable outcomes when patients are compliant, one must appreciate that bracing itself may be stressful and traumatic experience, and compliance with a bracing protocol is likely to be dependent upon patients’ physical, emotional and social well-being. Using the BrQ, we sought to explore relationships between QoL and compliance with treatment. METHODS: The BrQ was administered to 31 AIS patients after a minimum of 1 year of wearing a brace for 1 year. Subjects were 13-16 year-old girls with significant deformity (Cobb angles 25-40 degrees). Participants were divided into two groups according to their level of compliance with the bracing protocol. BrQ sub- and total scores were compared between the two groups using the t-test for comparison of means. RESULTS: Twenty patients were classified as compliant and 11 as non-compliant. Mean total BrQ scores (expressed as % of possible) were 83.7 for the compliant group and 64.4 for the non-compliant group (p < 0.001). The compliant group scored significantly higher in six of the eight domains that make up the BrQ. Compliant patients had greater vitality and self esteem, and functioned better in those domains covering physical, emotional and social aspects of QoL. CONCLUSIONS: Poor QoL adversely affects compliance in AIS patients requiring a brace. Non-compliant patients lack vitality and self esteem, and function poorly in the physical, emotional and social domains. Quality of life for adolescents with idiopathic scoliosis may catalyze more psycho-social coping strategies than their physical deformity and its consequences. It is important for remedial programmes to consider personal, peer and family issues as part of improving QoL, promoting compliance and correcting deformity.